On April 27, 2026, the U.S. Food and Drug Administration (FDA) updated its Cosmetic Product Ingredient Statement (CPIS) system guidance, introducing a new mandatory classification code — COS-PLS-2026 — for plant stem cell extracts (e.g., from apple, grape, or ginseng) in cosmetic ingredient submissions. Effective July 1, 2026, all such ingredients must be reported under this code, accompanied by a process description document certified to ISO 22000 standards for plant cell culture. This change directly affects skincare OEM manufacturers in China exporting to the U.S. market.

Event Overview

The U.S. FDA issued an update to its CPIS system operational guidance on April 27, 2026. Starting July 1, 2026, cosmetic product ingredient submissions containing plant stem cell extracts must use the newly assigned code COS-PLS-2026. Submitters are also required to upload a documented description of the plant cell culture process, verified against ISO 22000 food safety management standards. The guidance applies to all entities filing ingredient statements via CPIS, including foreign manufacturers and U.S. importers.

Which Subsectors Are Affected

Skincare OEM/ODM Manufacturers (China-based)

These firms formulate and produce finished skincare products for U.S.-based brands. Because they often source or incorporate plant stem cell extracts into formulations — especially in anti-aging or ‘bio-active’ lines — they will bear primary responsibility for accurate CPIS reporting. Impact manifests in revised internal documentation workflows, updated formulation records, and additional validation requirements for raw material suppliers.

Ingredient Suppliers & Distributors (Asia-Pacific)

Suppliers providing plant stem cell extracts (e.g., apple meristem, grape callus extracts) to OEMs must now ensure their technical dossiers include ISO 22000-aligned process documentation. Distributors acting as U.S. agents or responsible parties may face increased due diligence obligations when onboarding new extract-based ingredients.

U.S. Importers & Brand Holders

As the legal filers of CPIS submissions, U.S. importers and brand owners must verify that submitted ingredient data — including correct coding and supporting files — complies with the new requirement. Non-compliance risks delayed CPIS acceptance, which may affect product listing timelines and shelf readiness.

Regulatory & Compliance Service Providers

Firms offering CPIS filing support, regulatory consulting, or technical dossier preparation must update their templates, checklists, and training materials to reflect the COS-PLS-2026 code and ISO 22000 documentation standard. Their service scope now explicitly includes verification of plant cell culture process descriptions.

What Relevant Companies or Practitioners Should Watch and Do Now

Monitor official FDA communications for implementation clarifications

The FDA’s April 27 guidance is procedural, not regulatory — it does not amend the Federal Food, Drug, and Cosmetic Act or define ‘plant stem cell extract’ legally. Companies should track any follow-up FAQs, webinars, or notice letters from FDA’s Office of Cosmetics and Colors, particularly regarding acceptable formats for ISO 22000-aligned process documents.

Identify and map current formulations containing plant stem cell extracts

OEMs and brands should conduct an internal audit of active SKUs and development pipelines to identify all products containing apple, grape, ginseng, or other plant-derived stem cell extracts. Mapping should include supplier names, INCI names, batch-level documentation status, and whether ISO 22000 process descriptions are already available.

Distinguish between policy signal and operational readiness

This update signals heightened FDA attention on biotechnologically derived botanical ingredients — but it does not constitute a ban, safety assessment mandate, or premarket approval requirement. Companies should avoid over-interpreting the change as evidence of broader regulatory escalation, while still treating the July 1 deadline as operationally binding for CPIS submissions.

Prepare supplier engagement and documentation handover protocols

Since ISO 22000 certification applies to food safety management systems — not necessarily cosmetic manufacturing — suppliers may need time to adapt existing documentation. OEMs and importers should initiate communication with key extract suppliers now to clarify expectations, review draft process descriptions, and establish internal deadlines ahead of the July 1 cutoff.

Editorial Perspective / Industry Observation

Observably, this CPIS update reflects a targeted administrative refinement rather than a sweeping regulatory shift. It formalizes tracking for a narrow, high-profile ingredient category without altering safety evaluation pathways or labeling rules. Analysis shows the FDA is using CPIS — a voluntary but widely adopted ingredient disclosure tool — to strengthen data granularity for emerging ingredient types. From an industry perspective, this is best understood as a signal of increasing traceability expectations for biotech-derived botanicals, not an immediate compliance crisis. Continued monitoring is warranted, particularly for whether similar codes emerge for other cultured-ingredient categories (e.g., fungal mycelium extracts, lab-grown algae).

Conclusion

This CPIS update introduces a specific, actionable requirement for one ingredient class — plant stem cell extracts — and underscores the growing importance of precise, standardized ingredient reporting in U.S. cosmetic regulation. It does not represent a fundamental change in regulatory philosophy or enforcement posture, but it does raise the bar for documentation rigor among supply chain participants. Currently, it is more appropriately understood as a procedural alignment step than a strategic inflection point — yet one requiring timely, practical response from affected stakeholders.

Source Attribution

Main source: U.S. FDA CPIS Guidance Update Notice, published April 27, 2026.
Areas under ongoing observation: FDA’s forthcoming FAQ or supplemental guidance on acceptable ISO 22000 documentation scope for non-food applications; potential future expansion of COS-PLS codes to other plant cell culture derivatives.